Black Diamond Therapeutics Inc’s recently made public that its 10% Owner BIOTECH GROWTH N V unloaded Company’s shares for reported $12.0 million on Mar 19 ’25. In the deal valued at $2.07 per share,5,784,292 shares were sold. As a result of this transaction, BIOTECH GROWTH N V now holds 2,733,547 shares worth roughly $5.77 million.
Then, Versant Venture Capital VI, L. sold 221,600 shares, generating $1,400,556 in total proceeds. Upon selling the shares at $6.32, the 10% Owner now owns 3,726,341 shares.
Before that, David Epstein bought 50,000 shares. Black Diamond Therapeutics Inc shares valued at $310,000 were divested by the Former Employer at a price of $6.20 per share.
Raymond James initiated its Black Diamond Therapeutics Inc [BDTX] rating to an Outperform in a research note published on July 31, 2024; the price target was $20. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in mid July with a ‘”an Overweight”‘ rating. Stifel also remained covering BDTX and has increased its forecast on June 30, 2023 with a “Buy” recommendation from previously “Hold” rating. H.C. Wainwright revised its rating on June 28, 2023. It rated BDTX as “a Buy” which previously was an “a Neutral”.
Price Performance Review of BDTX
On Monday, Black Diamond Therapeutics Inc [NASDAQ:BDTX] saw its stock jump 8.21% to $2.11. Over the last five days, the stock has gained 20.57%. Black Diamond Therapeutics Inc shares have fallen nearly -1.40% since the year began. Nevertheless, the stocks have fallen -61.21% over the past one year.
How much short interest is there in Black Diamond Therapeutics Inc?
A steep rise in short interest was recorded in Black Diamond Therapeutics Inc stocks on 2025-04-30, dropping by -0.74 million shares to a total of 9.44 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 10.17 million shares. There was a decline of -7.8%, which implies that there is a negative sentiment for the stock.
